MedTrace Logo

Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma

NCT00937183 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-08-19

No results posted yet for this study

Summary

RATIONALE: Biological therapies, such as a dendritic cell vaccine made with a patient's cancer cells, may stimulate the immune system in different ways and stop cancer cells from growing.

PURPOSE: This phase I/II trial is studying the side effects of dendritic cell vaccine and to see how well it works in treating patients with indolent B-cell lymphoma or multiple myeloma.

Conditions

  • Lymphoma
  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

BIOLOGICAL

autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine

BIOLOGICAL

autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine

BIOLOGICAL

autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine

Sponsors & Collaborators

  • Jan Walewski

    lead OTHER

Principal Investigators

  • Jan Walewski, MD · Maria Sklodowska-Curie National Research Institute of Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2017-06-30
Completion
2017-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00937183 on ClinicalTrials.gov